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Corrigendum
Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line 
treatment for metastatic castration-resistant prostate cancer. 
Drug Design, Development and Therapy. 2011;5:117–124.
The drug Jevtana was incorrectly named Jentava in   
Table 4.